Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$298.71+4.90 (+1.67%)
Close on Nov 18, 2026Market cap $5.98BP/E 130.4Yield –
Ligand Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Ligand Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was $91.03M, up 185.2% year over year. For fiscal 2025 it was $49.36M, down 49.1% from the year before. Over ten years it grew 1.7% a year on average. The highest annual figure on record is $194.06M in fiscal 2018.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.36M | -49.1% |
| FY2024 | Dec 31, 2024 | $97.05M | +95.8% |
| FY2023 | Dec 31, 2023 | $49.58M | -64.0% |
| FY2022 | Dec 31, 2022 | $137.85M | +74.9% |
| FY2021 | Dec 31, 2021 | $78.80M | +44.4% |
| FY2020 | Dec 31, 2020 | $54.59M | – |
| FY2019 | Dec 31, 2019 | -$29.34M | -115.1% |
| FY2018 | Dec 31, 2018 | $194.06M | +119.1% |
| FY2017 | Dec 31, 2017 | $88.57M | +45.8% |
| FY2016 | Dec 31, 2016 | $60.73M | +45.5% |
| FY2015 | Dec 31, 2015 | $41.73M | +102.9% |
| FY2014 | Dec 31, 2014 | $20.57M | -0.6% |
| FY2013 | Dec 31, 2013 | $20.69M | +12750.9% |
| FY2012 | Dec 31, 2012 | $161.00K | – |
| FY2011 | Dec 31, 2011 | -$1.17M | – |
| FY2010 | Dec 31, 2010 | -$27.07M | – |
| FY2009 | Dec 31, 2009 | -$33.80M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$27.59M | -310.8% |
| Q2 FY2026 | Jun 30, 2026 | $24.02M | +52.0% |
| Q1 FY2026 | Mar 31, 2026 | $48.69M | – |
| Q4 FY2025 | Dec 31, 2025 | $45.92M | +61.3% |
| Q3 FY2025 | Sep 30, 2025 | $13.09M | -64.2% |
| Q2 FY2025 | Jun 30, 2025 | $15.80M | +18.7% |
| Q1 FY2025 | Mar 31, 2025 | -$25.45M | -235.8% |
| Q4 FY2024 | Dec 31, 2024 | $28.47M | +253.0% |
| Q3 FY2024 | Sep 30, 2024 | $36.53M | +377.8% |
| Q2 FY2024 | Jun 30, 2024 | $13.31M | – |
| Q1 FY2024 | Mar 31, 2024 | $18.73M | -44.8% |
| Q4 FY2023 | Dec 31, 2023 | $8.07M | -84.9% |
| Q3 FY2023 | Sep 30, 2023 | $7.65M | -62.7% |
| Q2 FY2023 | Jun 30, 2023 | -$82.00K | -100.7% |
| Q1 FY2023 | Mar 31, 2023 | $33.95M | -34.7% |
| Q4 FY2022 | Dec 31, 2022 | $53.47M | +93.4% |
| Q3 FY2022 | Sep 30, 2022 | $20.49M | +2.3% |
| Q2 FY2022 | Jun 30, 2022 | $11.88M | -41.7% |
| Q1 FY2022 | Mar 31, 2022 | $52.01M | +383.6% |
| Q4 FY2021 | Dec 31, 2021 | $27.64M | +5047.5% |
| Q3 FY2021 | Sep 30, 2021 | $20.03M | +57.1% |
| Q2 FY2021 | Jun 30, 2021 | $20.38M | -16.4% |
| Q1 FY2021 | Mar 31, 2021 | $10.75M | -36.4% |
| Q4 FY2020 | Dec 31, 2020 | $537.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $12.75M | – |
| Q2 FY2020 | Jun 30, 2020 | $24.38M | – |
| Q1 FY2020 | Mar 31, 2020 | $16.92M | -62.6% |
| Q4 FY2019 | Dec 31, 2019 | -$7.34M | -122.5% |
| Q3 FY2019 | Sep 30, 2019 | -$6.20M | -122.9% |
| Q2 FY2019 | Jun 30, 2019 | -$61.06M | -182.9% |
| Q1 FY2019 | Mar 31, 2019 | $45.26M | -25.5% |
| Q4 FY2018 | Dec 31, 2018 | $32.57M | +4.0% |
| Q3 FY2018 | Sep 30, 2018 | $27.08M | -2.1% |
| Q2 FY2018 | Jun 30, 2018 | $73.64M | +609.1% |
| Q1 FY2018 | Mar 31, 2018 | $60.76M | +216.1% |
| Q4 FY2017 | Dec 31, 2017 | $31.31M | +67.2% |
| Q3 FY2017 | Sep 30, 2017 | $27.65M | – |
| Q2 FY2017 | Jun 30, 2017 | $10.39M | – |
| Q1 FY2017 | Mar 31, 2017 | $19.22M | – |
| Q4 FY2016 | Dec 31, 2016 | $18.73M | – |
See a number that looks wrong?